Read More
Clinical Trials

Advancing novel candidates with the highest likelihood of driving significant benefit for patients.

We’re committed to evolving immunology. Our pipeline includes programs that are targeted to address highly prevalent inflammatory diseases. Our goal is to drive meaningful advances for patients with these diseases, designing all our programs to deliver best-in-class profiles.

EVO756 is an orally administered, highly selective MRGPRX2 inhibitor being developed for patients with chronic spontaneous urticaria who remain symptomatic despite H1 antihistamine treatment. Evommune recently announced positive proof-of-concept in a Phase 1 clinical trial, evaluating the safety/tolerability and preliminary activity of EVO756 in healthy volunteers and the initiation of a Phase 2 Trial of EVO756 in Chronic Inducible Urticaria.

STUDY
TRIAL OVERVIEW
Program:
EVO756-CIU001
Indication:
Chronic Inducible Urticaria (CINDU)
Status:
Phase 2a, Ongoing

EVO756-CIU001 is a multi-center, Phase 2a study evaluating the safety, tolerability, and efficacy of EVO756 in adults with chronic inducible urticaria (either cold urticaria or symptomatic dermographism). All participants will receive open-label treatment with EVO756, once daily, for a 4-week treatment period. Participants will be evaluated for safety and efficacy at weekly visits during treatment and return to the clinic for final assessments 2 weeks following the last dose of study drug.

Program:
EVO756-HV001
Indication:
Chronic Spontaneous Urticaria (CSU)
Status:
Phase 1, Completed

EVO756-HV001 is a Phase 1 randomized, double-blind, placebo-controlled study to evaluate EVO756 in healthy adults. The study is conducted in 2 parts. Part A will evaluate the safety and pharmacokinetics of single oral ascending doses of EVO756 in 7 cohorts of study participants and Part B will evaluate the safety, pharmacokinetics, and pharmacodynamics (effects on mast cells and skin reactivity) of EVO756 after 14 days of oral dosing in 5 cohorts of study participants.

Expanded Access Policy

Currently, Evommune’s investigational therapies are not available on an expanded access or right-to-try basis for new patients. In the event Evommune decides to consider expanded access or right-to-try use, Evommune will evaluate and respond to each request that it receives on a case-by-case basis. For more information on Evommune’s investigational therapies and ongoing clinical trials, please visit clinicaltrials.gov.

We are focused on novel therapies that target the drivers of chronic inflammatory disease.